Skip to main content

Table 1 Baseline characteristics

From: Combined evaluation of coronary artery disease and high-sensitivity cardiac troponin T for prediction of adverse events in patients with hypertrophic cardiomyopathy

Variables All patients (n = 162) NCA, normal hs-cTnT (n = 54) CAD, normal hs-cTnT (n = 23) NCA, elevated hs-cTnT (n = 53) CAD, elevated hs-cTnT (n = 32) P value
Age (years) 57.5 ± 13.5 52.2 ± 12.5 63.3 ± 11.5 55.9 ± 14.4 64.6 ± 10.1 < 0.001
Gender, male 95 (58.6%) 31 (57.4%) 16 (69.6%) 30 (56.6%) 18 (56.2%) 0.722
Family history of HCM 10 (6.2%) 3 (5.6%) 1 (4.3%) 4 (7.5%) 2 (6.2%) 0.952
Family history of SCD 4 (2.5%) 1 (1.9%) 1 (4.3%) 2 (3.8%) 0 (0.0%) 0.658
Current or prior tobacco use 60 (37.0%) 18 (33.3%) 13 (56.5%) 15 (28.3%) 14 (43.8%) 0.093
NYHA class III/IV 52 (32.1%) 10 (18.5%) 7 (30.4%) 22 (41.5%) 13 (40.6%) 0.050
Symptoms
Chest pain 121 (74.7%) 41 (75.9%) 18 (78.3%) 35 (66.0%) 27 (84.4%) 0.274
Palpitations 64 (39.5%) 22 (40.7%) 8 (34.8%) 23 (43.4%) 11 (34.4%) 0.816
Syncope/pre-syncope 47 (29.0%) 16 (29.6%) 7 (30.4%) 20 (37.7%) 4 (12.5%) 0.101
Dyspnea 98 (60.5%) 29 (53.7%) 13 (56.5%) 34 (64.2%) 22 (68.8%) 0.493
Comorbidities
Atrial fibrillation 18 (11.1%) 4 (7.4%) 4 (17.4%) 5 (9.4%) 5 (15.6%) 0.479
Hypertension 64 (39.5%) 14 (25.9%) 14 (60.9%) 15 (28.3%) 21 (65.6%) < 0.001
Diabetes 15 (9.3%) 4 (7.4%) 3 (13.0%) 3 (5.7%) 5 (15.6%) 0.396
Vascular diseases 18 (11.1%) 1 (1.9%) 0 (0.0%) 5 (9.4%) 12 (37.5%) < 0.001
Therapies       
Aspirin 38 (23.5%) 8 (14.8%) 8 (34.8%) 6 (11.3%) 16 (50.0%) < 0.001
Clopidogrel 14 (8.6%) 2 (3.7%) 1 (4.3%) 3 (5.7%) 8 (25.0%) 0.003
Warfarin 8 (4.9%) 2 (3.7%) 0 (0.0%) 3 (5.7%) 3 (9.4%) 0.428
Statins 69 (42.6%) 15 (27.8%) 15 (65.2%) 15 (28.3%) 24 (75.0%) < 0.001
Beta-blocker 131 (80.9%) 44 (81.5%) 21 (91.3%) 42 (79.2%) 24 (75.0%) 0.487
Diltiazem 10 (6.2%) 4 (7.4%) 2 (8.7%) 2 (3.8%) 2 (6.2%) 0.820
ICD 7 (4.3%) 1 (1.9%) 0 (0.0%) 5 (9.4%) 1 (3.1%) 0.446
Pacemaker 4 (2.5%) 1 (1.9%) 1 (4.3%) 1 (1.9%) 1 (3.1%)  
Septal myectomy 1 (0.6%) 0 (0.0%) 0 (0.0%) 1 (1.9%) 0 (0.0%) 0.293
Alcohol septal ablation 28 (17.3%) 14 (25.9%) 2 (8.7%) 6 (11.3%) 6 (18.8%)  
Echocardiography data
LVEDD (mm) 44.4 ± 5.6 43.9 ± 5.1 44.7 ± 4.8 44.6 ± 6.9 44.7 ± 4.5 0.883
LA diameter (mm) 40.7 ± 6.8 38.8 ± 6.3 40.4 ± 7.2 42.3 ± 7.3 41.3 ± 5.9 0.056
MWT (mm) 18.9 ± 4.8 18.6 ± 5.0 17.1 ± 3.1 20.0 ± 5.4 19.1 ± 4.1 0.108
LVEF (%) 67.5 ± 8.6 70.3 ± 4.7 68.9 ± 5.2 65.3 ± 11.9 65.6 ± 7.8 0.008
LVOT obstruction 78 (48.1%) 27 (50.0%) 11 (47.8%) 17 (32.1%) 23 (71.9%) 0.005
Biochemical markers
Hs-cTnT (ng/L) 30.9 ± 40.1 8.8 ± 3.5 9.4 ± 3.0 47.8 ± 43.1 55.5 ± 53.9 < 0.001
LDL-C (mmol/L) 2.5 ± 0.8 2.6 ± 0.8 2.3 ± 0.7 2.4 ± 0.8 2.4 ± 0.8 0.358
HDL-C (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.2 ± 0.4 1.4 ± 0.5 1.3 ± 0.5 0.186
  1. Values are mean ± SD or n (%)
  2. NCA normal coronary artery, hs-cTnT high-sensitivity cardiac troponin T, CAD coronary artery disease, HCM hypertrophic cardiomyopathy, SCD sudden cardiac death, ICD implantable cardioverter defibrillator, LVEDD left ventricular end-diastolic dimension, LA left atrial, MWT maximal left ventricular wall thickness, LVEF left ventricular ejection fraction, LVOT left ventricular outflow tract, LDL-C low density lipoprotein cholesterin, HDL-C high density lipoprotein cholesterin